Table 1.
Demographic and biomarker information of the TRIAD cohort by clinical and biomarker-defined groups
| Young adults (n = 22) |
CU- (n = 54) |
CU + (n = 26) |
MCI + (n = 19) |
AD (n = 19) |
Non-AD (n = 16) |
FTD (n = 9) |
P-value | |
|---|---|---|---|---|---|---|---|---|
| Age, years | 23.3 (1.8) | 71.0 (7.4) | 72.2 (7.5) | 72.2 (6.1) | 64.6 (7.1) | 70.5 (9.5) | 62.4 (6.2) | < 0.0001* |
| Female, n (%) | 14 (63) | 34 (63) | 17 (65) | 9 (47) | 8 (42) | 7 (43) | 6 (66) | 0.44 |
| Education, years | 16.7 (1.5) | 14.9 (3.6) | 14.4 (2.7) | 15.8 (2.8) | 15.4 (3.1) | 13.7 (4.0) | 14.4 (4.0) | 0.08 |
| APOE-ε4 carriers, n (%) | 6 (27) | 17 (31) | 8 (30) | 12 (63) | 13 (72) | 4 (26) | 1 (11) | 0.002* |
| MMSE | 29.7 (0.5) | 29.1 (1.0) | 29.3 (0.8) | 27.9 (1.8) | 20.0 (6.3) | 26.7 (2.8) | 26.0 (7.3) | < 0.0001* |
| Aß PET (SUVR) | 1.18 (0.06) | 1.26 (0.10) | 1.96 (0.42) | 2.40 (0.42) | 2.35 (0.44) | 1.33 (0.12) | 1.15 (0.08) | < 0.0001* |
| Tau PET (SUVR) | 0.82 (0.08) | 0.91 (0.10) | 1.00 (0.15) | 1.56 (0.45) | 2.09 (0.55) | 1.11 (0.65) | 0.79 (0.10) | < 0.0001* |
| p-Tau181 (fmol/mL) | 0.86 (0.25) | 1.15 (0.33) | 1.41 (0.49) | 1.79 (0.71) | 1.74 (0.69) | 1.48 (0.95) | 0.98 (0.43) | < 0.0001* |
| p-Tau199 (fmol/mL) | 0.17 (0.06) | 0.24 (0.05) | 0.29 (0.08) | 0.35 (0.12) | 0.43 (0.17) | 0.32 (0.24) | 0.24 (0.07) | < 0.0001* |
| p-Tau202 (fmol/mL) | 0.06 (0.02) | 0.09 (0.03) | 0.10 (0.03) | 0.13 (0.06) | 0.15 (0.05) | 0.12 (0.06) | 0.09 (0.04) | < 0.0001* |
| p-Tau205 (fmol/mL) | 0.01 (0.004) | 0.02 (0.01) | 0.03 (0.01) | 0.08 (0.07) | 0.11 (0.05) | 0.05 (0.09) | 0.02 (0.009) | < 0.0001* |
| p-Tau217 (fmol/mL) | 0.04 (0.01) | 0.08 (0.04) | 0.20 (0.13) | 0.40 (0.25) | 0.54 (0.31) | 0.25 (0.43) | 0.12 (0.17) | < 0.0001* |
| p-Tau231 (fmol/mL) | 0.02 (0.02) | 0.07 (0.07) | 0.29 (0.29) | 0.50 (0.26) | 0.60 (0.38) | 0.31 (0.53) | 0.12 (0.24) | < 0.0001* |
| p-Tau396 (fmol/mL) | 0.03 (0.01) | 0.05 (0.02) | 0.06 (0.03) | 0.07 (0.02) | 0.06 (0.03) | 0.06 (0.03) | 0.04 (0.02) | < 0.0001* |
Data shown as mean (SD) or n (%), as appropriate. Variables were compared with a one-way ANOVA adjusted and P-values are presented. Aβ status for group definition was based on PET visual rating
Abbreviations: Aβ amyloid-β, AD Alzheimer’s Disease dementia, CU- Aβ-negative cognitively unimpaired, CU + Aβ-positive cognitively unimpaired, FTD Aβ- Fronto-temporal dementia, MCI + Aβ-positive mild cognitive impairment, MMSE Mini-Mental State Examination, Non-AD Aβ-negative MCI and “AD” dementia, SUVR Standardized uptake value ratio